When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BMY - Sell Celgene Buy Bristol-Myers: Counting The Profits At The Halfway Mark
Bristol-Myers Squibb Company
Celgene Or Bristol-Myers: Comparing The Two
Bristol-Myers Squibb (BMY) have successfully offered to acquire Celgene (CELG), and the transaction is expected to complete in early January 2020. This means a shareholder in Celgene no longer has an interest in the Celgene business, as the business has been conditionally sold to Bristol-Myers Squibb (which I will hereafter abbreviate to "BMS"). A Celgene share entitles the owner to 1 share in BMS plus $50 in cash, plus a Contingent Value Right ((CVR)) for which BMS has estimated a current fair value of $3.74